POST Triheptanoin
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontal Lobe Hypometabolism
Conditions
Frontal Lobe Hypometabolism
Trial Timeline
Apr 1, 2016 → Aug 8, 2018
NCT ID
NCT02679235About POST Triheptanoin
POST Triheptanoin is a phase 1/2 stage product being developed by Ultragenyx Pharmaceutical for Frontal Lobe Hypometabolism. The current trial status is completed. This product is registered under clinical trial identifier NCT02679235. Target conditions include Frontal Lobe Hypometabolism.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02679235 | Phase 1/2 | Completed |
Competing Products
1 competing product in Frontal Lobe Hypometabolism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |